Skip to main content

Advertisement

SpringerLink
Log in

Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer

  • Research Articles
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

Organ preservation has been investigated in patients (p) with infiltrating transitional cell carcinoma (TCC) of the bladder over the past decade as an alternative to radical cystectomy. This is a trimodal schedule study, including transurethral resection of bladder tumor (TURB), neoadjuvant chemotherapy and concomitant radiochemotherapy (RTC).

Patients and methods

From April 1996 until August 2005, 29 evaluable patients (p) with T2-T3NXM0 bladder cancer were enrolled. After a transurethral resection of bladder tumor (TURB), we administered 2 cycles of induction chemotherapy with CMV (15 p) or Gemcitabine-Cisplatin (14 p) followed by radiotherapy 45 Gy 1.8 Gy/fraction and two cycles of concomitant cisplatin 70 mg/m2. 2–3 weeks later, a cystoscopy with tumor-site biopsy was performed. If complete histological response, p were treated with consolidation radiotherapy until 64.8 Gy. For p with residual or recurrent tumor, cystectomy was performed.

Results

We included 28 men and 1 women (median age 63, range 39–72 years) with PS (ECOG) 0–1. The stage was: 21 p T2; 6 p T3a; and 2 p T3b. Toxicity was higher in CMV compared with Gem-Cis: grade 3/4 neutropenia 4/15 (26%) vs 1/14 (7%); febrile neutropenia 3/15 (20%) vs 1/14 (7%); grade 3/4 trombocytopenia 2/15 (13%) vs 1/14 (7%). Toxicities with concomitant RCT were low-moderate: urocystitis (26%) and enteritis (18%). Response: microscopically complete TURB was obtained in 20 p (69%), but not in 9 p (31%) (7 microscopic, and 2 macroscopic residual tumor). We found a complete histologic response after induction RCT in 25 p (86%). After a median follow-up of 69.4 months (m) (range: 8–97.7), there were 8 deaths, with a overall survival of 72%. Furthermore 14 of 29 p (48%) were alive with intact bladder, and median survival time with intact bladder was 63.6 m (50.1–77.2); were predictive of best outcome T2 stage vs T3 (p<0.0001), and complete histologic resection in initial TURB vs residual tumor (p=0.0004).

Conclusions

Combined treatment provide high response rates and can be offered as an alternative option to radical cystectomy in selected patients with TCC. Patients with T2 stage and complete histologic resection in initial TURB had the best outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tsukamoto T, Kitamura H, Takahashi A, et al. Treatment of invasive bladder cancer: Lessons from the past and perspective for the future. Jpn J Clin Oncol. 2004; 54(6):295–306.

    Article  Google Scholar 

  2. Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol. 2005;174:14–20.

    Article  PubMed  CAS  Google Scholar 

  3. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564–9.

    PubMed  CAS  Google Scholar 

  4. Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;17:3068–77.

    Google Scholar 

  5. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–66.

    Article  PubMed  CAS  Google Scholar 

  6. Advanced bladder cancer (ABC). meta-analysis collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361:1927–34.

    Article  CAS  Google Scholar 

  7. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001;345:1890–900.

    Article  PubMed  CAS  Google Scholar 

  8. O’Sullivan B, Bell R, Bramwell V. Sarcomas of the soft tissues, in Souhami R, Tannock I, Hohenberger P, et al. (eds): Oxford Textbook of Oncology, ed 2. Oxford, United Kingdom, Oxford University Press, 2002; p. 2495–523.

    Google Scholar 

  9. Singletary SE. Minimally invasive techniques in breast cancer treatment. Semin Surg Oncol 2001;20:246–50.

    Article  PubMed  CAS  Google Scholar 

  10. Willett CG. Organ preservation in anal and rectal cancers. Curr Opin Oncol. 1996; 8:329–33.

    Article  PubMed  CAS  Google Scholar 

  11. Rödel C, Grabenbauer GG, Kühn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol. 2002;20:5061–71.

    Article  Google Scholar 

  12. Dunst J, Rodel C, Zietman A, et al. Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy. Semin Surg Oncol. 2001;20:24–32.

    Article  PubMed  CAS  Google Scholar 

  13. Shipley WU, Kaufman DS, Tester WJ, Pilepich MV, Sandler HM. Radiation Therapy Oncology Group. Overview of bladder cancer trials in the Radiation Therapy Oncology Group, Cancer. 2003;97(8 Suppl):S2115–9.

    Article  CAS  Google Scholar 

  14. Sauer R, Birkenhake S, Kuhn R, Wittekind C, Schrott KM, Martus P. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys. 1998;40:121–7.

    Article  PubMed  CAS  Google Scholar 

  15. Tirindelli D, Arcangeli G, Cruciani E. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy. Cancer. 2004;101:2440–8.

    Google Scholar 

  16. Shu HK, Lee TT, Vigneauly E, et al. Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer. Urology. 2001;57:102–7.

    Article  PubMed  CAS  Google Scholar 

  17. Arias F, Dominguez MA, Martinez E, et al. Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiot Oncol Biol Phys. 2000; 47:373–8.

    Article  CAS  Google Scholar 

  18. Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 1996;14:119–26.

    PubMed  CAS  Google Scholar 

  19. Kachnic LA, Kaufman DS, Heney NM, et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 1997;15:1022–29.

    PubMed  CAS  Google Scholar 

  20. Fellin G, Graffer U, Bolner A, Ambrosini G, Caffo O, Luciani L. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study. Br J Urol. 1997;80:44–9.

    PubMed  CAS  Google Scholar 

  21. Shipley WU, Winter KA, Kaufman DS. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998;16:3576–83.

    PubMed  CAS  Google Scholar 

  22. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med. 1993;329:1377–82.

    Article  PubMed  CAS  Google Scholar 

  23. Cervek J, Cufer T, Zakotrik B, et al. Invasive bladder cancer: our experience with bladder sparing approach. Int J Radiot Oncol Biol Phys. 1998;41:273–8.

    Article  CAS  Google Scholar 

  24. Tirindelli D, Arcangeli G, Cruciani E, et al. Conservative treatment of invasive bladder carcinoma by transurethral resection, protacted intravenous infusion chemotherapy, and hyperfractionated radiotherapy. Cancer. 2004;101:2540–8.

    Article  Google Scholar 

  25. Einstein AB, Wolf M, Halliday KR, et al. Combination transurethral resection, systemic chemotherapy, and pelvis radiotherapy for invasive (T2–T4) bladder cancer unsuitable for cystectomy: a phase I/II Southwestern Oncology Group Study. Urology. 1996;47:652–7.

    Article  PubMed  Google Scholar 

  26. Jichlinski P. New diagnostic strategies in the detection and staging of bladder cancer. Curr Opin Urol. 2003;13:351–5.

    Article  PubMed  Google Scholar 

  27. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666–75.

    PubMed  CAS  Google Scholar 

  28. Sherwood BT, Jones DD, Mellon JK, Kockelbergh RC, Steward WP, Symonds RP. Concomitant chemoradiotherapy for muscle-invasive bladder cancer: the way forward for bladder preservation? Clin Oncol. 2005;17:160–8.

    Article  CAS  Google Scholar 

  29. Montie JE. Against bladder sparing: surgery. J Urol. 1999;162:452–7.

    Article  PubMed  CAS  Google Scholar 

  30. Romero Fernández J, De la Torre Tomás A. Cancer de vejiga infiltrante: la hora del tratamiento conservador. Rev. Oncol. 2003;26:50–62.

    Google Scholar 

  31. Matos T, Cufer T, Cervek J, Bornstnar S, Kragelj B, Zumer-Pregelj M. Prognostic factors in invasive bladder carcinoma treated by combined modality protocol (organ-sparing approach). Int J Radiat Oncol Biol Phys. 2000;46:403–9.

    Article  PubMed  CAS  Google Scholar 

  32. Solsona E, Iborra I, Ricos J, et al. Outcome of a prospective study of selected patients with muscle-invasive bladder cancer treated with radical TUR alone followed for more than 15 years. Eur Urol. 2005;Suppl 4:S179 (abstr 706).

    Google Scholar 

  33. Herr H. Transurethral reseaction of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol. 2001;19:89–93.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiotherapy Oncology Service, Hospital Regional Universitario Carlos Haya, Málaga, Spain

    Raquel Delgado, Ismael Herruzo & Jorge Contreras

  2. Urology Service, Hospital Regional Universitario Carlos Haya, Málaga, Spain

    Víctor Baena,  del Rosal & Emilio García

  3. Urology Service, Hospital Antequera, Málaga, Spain

    Pilar Moreno

  4. Urology Service, Hospital Axarquía, Málaga, Spain

    José Luis Ruiz & Carlos Fuentes

  5. Sección de Oncologia Médica. Pabellón A, 3.a planta derecha. Secretaría de Oncología Médica, Hospital Regional Universitario Carlos Haya, Avda Carlos Haya, s/n, 29010, Málaga, Spain

    Manuel Cobo, Silvia Gil, Francisco Carabante, Juan José Bretón, José M., Esther Villar, Inmaculada Alés & Manuel Benavides

Authors
  1. Manuel Cobo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raquel Delgado
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Silvia Gil
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ismael Herruzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Víctor Baena
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Francisco Carabante
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pilar Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. José Luis Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Juan José Bretón
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. José M.
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. del Rosal
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Carlos Fuentes
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Paloma Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Emilio García
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Esther Villar
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Jorge Contreras
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Inmaculada Alés
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Manuel Benavides
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manuel Cobo.

Additional information

Radiotherapy Oncology Unit . CROASA, S.A.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cobo, M., Delgado, R., Gil, S. et al. Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer. Clin Transl Oncol 8, 903–911 (2006). https://doi.org/10.1007/s12094-006-0154-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-006-0154-1

Key words

Search

Navigation